|
|
|
|
Vol. 61, Issue 6, 1435-1443, June 2002
Digestive Diseases Branch, National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health, Bethesda,
Maryland (K.T., R.T.J.); and Department of Medicine, Peptide Research
Laboratories, Tulane University Health Sciences Center, New Orleans,
Louisiana (S.J.H., D.H.C.)
The mammalian bombesin peptides [gastrin-releasing peptide (GRP) and
neuromedin B (NMB)] are important in numerous biological and
pathological processes. These effects are mediated by the heptahelical
GRP receptor (GRPR) and NMB receptor (NMBR). GRP has high affinity for
GRPR and lower affinity for NMBR. Almost nothing is known about the
molecular basis for the selectivity of GRP. To address this question,
we first studied four loss-of-affinity GRPR chimeric receptors formed
by exchanging the four extracellular (EC) domains of GRPR with the
corresponding NMBR EC domains. Receptors were transiently expressed,
and affinities were determined by binding studies. Only substitution of
the third EC domain (EC3) of GRPR markedly decreased GRP affinity. In
the reverse study using gain-of-affinity NMBR chimeras, only
replacement of EC3 of NMBR markedly increased GRP affinity. Replacing
each of the 20 comparable EC3 amino acids that differed in the NMBR in
GRPR showed that two separate NMBR substitutions in the GRPR, Ile for Phe185 or Ile for Ala198, markedly decreased
GRP affinity. Additional point mutants demonstrated that an amino acid
with an aromatic ring in position 185 of GRPR and the size of the
backbone substitution in position 198 of GRPR were important for GRP
selectivity. These results demonstrate that selectivity of GRP for GRPR
over NMBR is primarily determined by two amino acid differences in the
EC3 domains of the receptor. Our results suggest that an interaction
between the aromatic ring of Phe185 of the GRPR with GRP is
the most important for GRP selectivity.
This article has been cited by other articles:
![]() |
R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ashour, L. Shan, J. H. Lee, W. Schlicher, K. Wada, E. Wada, and M. E. Sunday Bombesin Inhibits Alveolarization and Promotes Pulmonary Fibrosis in Newborn Mice Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1377 - 1385. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Grider Gastrin-releasing peptide is a modulatory neurotransmitter of the descending phase of the peristaltic reflex Am J Physiol Gastrointest Liver Physiol, December 1, 2004; 287(6): G1109 - G1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Moody, S. A. Mantey, T. K. Pradhan, M. Schumann, T. Nakagawa, A. Martinez, J. Fuselier, D. H. Coy, and R. T. Jensen Development of High Affinity Camptothecin-Bombesin Conjugates That Have Targeted Cytotoxicity for Bombesin Receptor-containing Tumor Cells J. Biol. Chem., May 28, 2004; 279(22): 23580 - 23589. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Subramaniam, K. Sugiyama, D. H. Coy, Y. Kong, Y. E. Miller, P. F. Weller, K. Wada, E. Wada, and M. E. Sunday Bombesin-like Peptides and Mast Cell Responses: Relevance to Bronchopulmonary Dysplasia? Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 601 - 611. [Abstract] [Full Text] [PDF] |
||||